Literature DB >> 21689625

The role of Pea3 group transcription factors in esophageal squamous cell carcinoma.

Hiu-Fung Yuen1, Cian M McCrudden, Ka-Kui Chan, Yuen-Piu Chan, Michelle Lok-Yee Wong, Kelvin Yuen-Kwong Chan, Ui-Soon Khoo, Simon Law, Gopesh Srivastava, Terence R Lappin, Kwok-Wah Chan, Mohamed El-Tanani.   

Abstract

The transcription factors Pea3, Erm, and Er81 can promote cancer initiation and progression in various types of solid tumors. However, their role in esophageal squamous cell carcinoma (ESCC) has not been elucidated. In this study, we found that the expression levels of Pea3 and Erm, but not that of Er81, were significantly higher in ESCC compared with nontumor esophageal epithelium. A high level of Pea3 expression was significantly correlated with a shorter overall survival in a cohort of 81 patients with ESCC and the subgroup with N1 stage tumor (Wilcoxon-Gehan test, P = 0.016 and P = 0.001, respectively). Pea3 was overexpressed in seven ESCC cell lines compared with two immortalized esophageal cell lines. Pea3 knockdown reduced cell proliferation and suppressed nonadherent growth, migration, and invasion in ESCC cells in vitro. In addition, Pea3 knockdown in ESCC cells resulted in a down-regulation of phospho-Akt and matrix metalloproteinase 13, whereas a significant positive correlation in the expression levels was observed between Pea3 and phospho-Akt (r = 0.281, P < 0.013) and between Pea3 and matrix metalloproteinase 13 in the human specimens (r = 0.462, P < 0.001). Moreover, Pea3 modulated the sensitivity of EC109 cells to doxorubicin, probably via reduced activity of the phosphatidylinositol 3-kinase-Akt-mammalian target of Rapamycin complex 1 pathway on Pea3 knockdown. In conclusion, our results suggest that Pea3 plays an important role in the progression of ESCC.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21689625      PMCID: PMC3157177          DOI: 10.1016/j.ajpath.2011.04.004

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  60 in total

1.  Cyclooxygenase-2 inhibitor NS398 enhances radiosensitivity of radioresistant esophageal cancer cells by inhibiting AKT activation and inducing apoptosis.

Authors:  Shao-Min Che; Xiao-Zhi Zhang; Lei Hou; Tian-Bao Song
Journal:  Cancer Invest       Date:  2010-08       Impact factor: 2.176

2.  Doxorubicin, cisplatin, and fluorouracil combination therapy for metastatic esophageal squamous cell carcinoma.

Authors:  M Honda; A Miura; Y Izumi; T Kato; T Ryotokuji; K Monma; J Fujiwara; H Egashira; T Nemoto
Journal:  Dis Esophagus       Date:  2010-11       Impact factor: 3.429

3.  Cooperation between AP1 and PEA3 sites within the progression elevated gene-3 (PEG-3) promoter regulate basal and differential expression of PEG-3 during progression of the oncogenic phenotype in transformed rat embryo cells.

Authors:  Z Su; Y Shi; P B Fisher
Journal:  Oncogene       Date:  2000-07-13       Impact factor: 9.867

4.  The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2.

Authors:  A L Hsu; T T Ching; D S Wang; X Song; V M Rangnekar; C S Chen
Journal:  J Biol Chem       Date:  2000-04-14       Impact factor: 5.157

5.  Proteomic approach to ETV5 during endometrial carcinoma invasion reveals a link to oxidative stress.

Authors:  Marta Monge; Eva Colas; Andreas Doll; Antonio Gil-Moreno; Josep Castellvi; Berta Diaz; Marta Gonzalez; Rafael Lopez-Lopez; Jordi Xercavins; Ramon Carreras; Francesc Alameda; Francesc Canals; Franco Gabrielli; Jaume Reventos; Miguel Abal
Journal:  Carcinogenesis       Date:  2009-05-14       Impact factor: 4.944

6.  Study of abnormal chromosome regions in esophageal squamous cell carcinoma by comparative genomic hybridization: relationship of lymph node metastasis and distant metastasis to selected abnormal regions.

Authors:  Noritaka Sakai; Yoshiaki Kajiyama; Yoshimi Iwanuma; Natumi Tomita; Takayuki Amano; Fuyumi Isayama; Kazutomo Ouchi; Masahiko Tsurumaru
Journal:  Dis Esophagus       Date:  2009-11-23       Impact factor: 3.429

7.  Cyclooxygenase-2 inhibition inhibits PI3K/AKT kinase activity in epithelial ovarian cancer.

Authors:  Shahab Uddin; Maqbool Ahmed; Azhar Hussain; Lina Assad; Fouad Al-Dayel; Prashant Bavi; Khawla S Al-Kuraya; Adnan Munkarah
Journal:  Int J Cancer       Date:  2010-01-15       Impact factor: 7.396

Review 8.  Epidemiology of esophageal cancer: Orient to Occident. Effects of chronology, geography and ethnicity.

Authors:  Michio Hongo; Yutaka Nagasaki; Tomotaka Shoji
Journal:  J Gastroenterol Hepatol       Date:  2009-05       Impact factor: 4.029

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

10.  Prostate cancer cells modulate osteoblast mineralisation and osteoclast differentiation through Id-1.

Authors:  H-F Yuen; Y-T Chiu; K-K Chan; Y-P Chan; C-W Chua; C M McCrudden; K-H Tang; M El-Tanani; Y-C Wong; X Wang; K-W Chan
Journal:  Br J Cancer       Date:  2009-12-15       Impact factor: 7.640

View more
  9 in total

Review 1.  ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors.

Authors:  Sangphil Oh; Sook Shin; Ralf Janknecht
Journal:  Biochim Biophys Acta       Date:  2012-03-08

Review 2.  New insights into the role of Runx1 in epithelial stem cell biology and pathology.

Authors:  Cornelia Johanna Franziska Scheitz; Tudorita Tumbar
Journal:  J Cell Biochem       Date:  2013-05       Impact factor: 4.429

3.  PEA3 transcription factors are downstream effectors of Met signaling involved in migration and invasiveness of Met-addicted tumor cells.

Authors:  Zoulika Kherrouche; Didier Monte; Elisabeth Werkmeister; Luc Stoven; Yvan De Launoit; Alexis B Cortot; David Tulasne; Anne Chotteau-Lelievre
Journal:  Mol Oncol       Date:  2015-07-15       Impact factor: 6.603

4.  SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas.

Authors:  Hideo Watanabe; Qiuping Ma; Shouyong Peng; Guillaume Adelmant; Danielle Swain; Wenyu Song; Cameron Fox; Joshua M Francis; Chandra Sekhar Pedamallu; David S DeLuca; Angela N Brooks; Su Wang; Jianwen Que; Anil K Rustgi; Kwok-kin Wong; Keith L Ligon; X Shirley Liu; Jarrod A Marto; Matthew Meyerson; Adam J Bass
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

5.  Impact of oncogenic driver mutations on feedback between the PI3K and MEK pathways in cancer cells.

Authors:  Hiu-Fung Yuen; Olga Abramczyk; Grant Montgomery; Ka-Kui Chan; Yu-Han Huang; Takehiko Sasazuki; Senji Shirasawa; Srivastava Gopesh; Kwok-Wah Chan; Dean Fennell; Pasi Janne; Mohamed El-Tanani; James T Murray
Journal:  Biosci Rep       Date:  2012-08       Impact factor: 3.840

6.  Overexpression of SRC-3 promotes esophageal squamous cell carcinoma aggressiveness by enhancing cell growth and invasiveness.

Authors:  Fang-Ping Xu; Yan-Hui Liu; Xin-Lan Luo; Fen Zhang; Hai-Yu Zhou; Yan Ge; Chao Liu; Jie Chen; Dong-Lan Luo; Li-Xu Yan; Ping Mei; Jie Xu; Heng-Guo Zhuang
Journal:  Cancer Med       Date:  2016-10-26       Impact factor: 4.452

7.  A novel crosstalk between CCAR2 and AKT pathway in the regulation of cancer cell proliferation.

Authors:  Michela Restelli; Martina Magni; Vincenzo Ruscica; Patrizia Pinciroli; Loris De Cecco; Giacomo Buscemi; Domenico Delia; Laura Zannini
Journal:  Cell Death Dis       Date:  2016-11-03       Impact factor: 8.469

8.  ETV4 collaborates with Wnt/β-catenin signaling to alter cell cycle activity and promote tumor aggressiveness in gastrointestinal stromal tumor.

Authors:  Shan Zeng; Adrian M Seifert; Jennifer Q Zhang; Teresa S Kim; Timothy G Bowler; Michael J Cavnar; Benjamin D Medina; Gerardo A Vitiello; Ferdinand Rossi; Jennifer K Loo; Nesteene J Param; Ronald P DeMatteo
Journal:  Oncotarget       Date:  2017-12-11

9.  MK2 and ETV1 Are Prognostic Factors in Esophageal Adenocarcinomas.

Authors:  Gerd Jomrich; Florian Maroske; Jasmin Stieger; Matthias Preusser; Aysegül Ilhan-Mutlu; Daniel Winkler; Ivan Kristo; Matthias Paireder; Sebastian Friedrich Schoppmann
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.